You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
野村:石药集团(1093.HK)首季业绩胜预期 评级“买入”
格隆汇 05-28 13:36

野村发表研究报告指,石药集团(1093.HK)今年首季业绩强劲胜市场预期。管理层预期,随着3月份医院的问诊服务恢复,药物销售增长会进一步加速。该行维持其“买入”投资评级,目标价24港元。

野村表示,截至今年3月份,石药有20只仿制药正等待中国国家药品监督管理局审批,料能在2020-2021财年能打入市场。野村又指,虽然石药开发内部管道产品,但预期石药会更加积极地发展后期管道产品,料能在2022-2023财年进入市场。

另外,石药计划在科创板双重上市,以支持新产品的推出。野村预期,新股发行能帮助石药筹集90-135亿元人民币资本。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account